Ifosfamide and Doxorubicin in Patients With Refractory Nasopharyngeal Carcinoma

Phase 2TerminatedNCT00484601

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins9 enrolled

Overview

This research is to test the effectiveness and toxicity of both Ifosfamide and Doxorubicin. It also aims to explore the relationship between EBV DNA and clinical response in patients with advanced naso-pharyngeal cancer which has been previously treated with chemotherapy.

Nasopharyngeal Cancer (NPC) is one of the common cancer in Southeast Asia. In this region NPC is associated with Epstein Barr Virus (EBV) chronic infection with EBV DNA identifiable in almost all the NPC tumors and patient's serum at the time of diagnosis. Chinese, especially cantonese has the highest incidence. Only about 30% of patients presents early disease and has a good treatment outcome (80% cure for stage I disease and 70% for stage II by radiation). This research is to test the effectiveness and toxicity of both Ifosfamide and Doxorubicin. It also aims to explore the relationship between EBV DNA and clinical response in patients with advanced naso-pharyngeal cancer which has been previously treated with chemotherapy. Investigators believe EBV infection is necessary to cause NPC and that EBV DNA levels in the blood may directly relate to the total size of the tumor. Because NPC patients in this situation have a poor outlook, we design this study to evaluate the combination of Ifosfamide and doxorubicin for further treatment. While this combination of medicines has been used in many other forms of cancer, it has not been tested in patients with NPC.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Refractory Nasopharyngeal Carcinoma

Interventions

IfosfamideDRUG

DoxorubicinDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Histological diagnosis of NPC * Age \> 18 years old * Measurable metastatic or recurrent disease (s) * Received one prior chemotherapy regimen for metastatic or recurrent NPC which relapsed or became refractory before entry. * ECOG PS 0, 1 or 2 * WBC \> 3,500/uL and ANC \> 1,500/uL Platelet \> 100,000/uL Creatinine - within normal limits SGOT \< 3 X UNL Bilirubin \< 2.0 mg/dL * Ejection fraction \> 45% and no history of myocardial infarction or congestive heart failure in the last 6 months. No history of cardiac ventricular arrythmia or ventricle tachycardia, or uncontrolled atrial fibrillation or supraventricular tachycardia with hemodynamic compromising status. * Random blood glucose level \< 250 mg * Signed informed consent Exclusion Criteria: * Received more than one prior chemotherapy for metastatic or recurrent disease * Ejection fraction \< 45% * WBC \< 3,500/UL or ANC \< 1,500/UL or P/t \< 100,000/UL or SCOT\> 3 x UNL or Bilirubin \> 2.0 mg/dL or Creatinine \> UNL * ECOG PS \> 3 * Hx of myocardial infarction within last 6 months * Random blood glucose level less than or equal 250 mg

Locations (1)

Johns Hopkins Singapore International Medical Center

Singapore, Singapore

Outcomes

Primary Outcomes

To evaluate the overall response rate and toxicity including complete response rate, response duration, time to treatment failure, and survival of ifosfamide and doxorubicin as the second line chemotherapy for patients with advanced NPC

Prematured termination, data is not analysed.

Time frame: May 2008

Secondary Outcomes

To correlate EBVDNA titer with clinical response

Prematured termination, data is not analysed.

Time frame: May 2008

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.